We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection (MRSA-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00859677
Recruitment Status : Completed
First Posted : March 11, 2009
Last Update Posted : June 14, 2017
Sponsor:
Collaborators:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to investigate the role of T helper 17 cells (Th17) in the pathogenesis of MRSA infections.

Condition or disease
HIV Infections Staphylococcal Infections

Study Design

Study Type : Observational
Actual Enrollment : 52 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection
Study Start Date : March 2009
Primary Completion Date : November 2010
Study Completion Date : August 26, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS MRSA
U.S. FDA Resources

Groups and Cohorts

Group/Cohort
1
HIV-positive and MRSA negative
2
HIV-positive and MRSA infected (skin/soft tissue)
3
HIV-positive and MRSA colonized
4
HIV-negative and MRSA negative
5
HIV-negative and MRSA infected (skin/soft tissue)
6
HIV-negative and MRSA colonized


Outcome Measures

Primary Outcome Measures :
  1. To compare distribution of Th17 cells and their functionality, in the peripheral blood of HIV-positive patients who are infected with MRSA with that of HIV-positive patients who are not colonized or infected with Staphylococcus aureus. [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Compare distribution of Th17 cells in the peripheral blood of groups of HIV-positive and HIV-negative participants who are colonized with MRSA as well as those who have a MRSA infection. [ Time Frame: 1 year ]
  2. Examine distribution of T cells, B cells, macrophages, dendritic cells, neutrophils, defensins, and IL-17 in T cell subsets in the skin [ Time Frame: 1 year ]
  3. Compare Th17 cells in peripheral blood of HIV-negative participants with MRSA infection with that of HIV-negative subjects not colonized of infected with Staph aureus. [ Time Frame: 1 year ]
  4. Collect information on factors that may play a role in development of MRSA colonization/infection. Includes demographic, hygienic, exercise-related, and sexual factors which may contribute to MRSA. [ Time Frame: 1 year ]

Biospecimen Retention:   Samples With DNA
Skin biopsy will be obtained.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
HIV-positive and negative patients with a recent screen for MRSA colonization or a history of MRSA infection will be asked to participate. Participants will be recruited by providers within the infectious disease clinics at the sites. In addtion, MRSA isolates will be monitored at the central laboratory and providers of patients with MRSA will be notified and asked to notify their patients of the opportunity to participate in this study.
Criteria

All participant inclusion criteria:

  • Greater or equal to 18 years of age
  • Willingness to undergo blood draw. Skin biopsy will be requested, but is optional

-AND-

HIV-positive and MRSA-negative Group:

  • Documented positive HIV test result
  • Negative colonization swabs for S. aureus within 14 days of enrollment
  • No evidence of skin/soft tissue infection

HIV-positive and MRSA-Colonization Group:

  • Documented positive HIV test result
  • History of of colonization with MRSA w/in 14 days of study enrollment

HIV-positive and MRSA Infection Group:

  • Documented positive HIV test result
  • Skin/soft tissue infection with a positive wound culture showing MRSA within 7 days of enrollment
  • MRSA infection is not associated with an intravenous catheter or other nosocomial procedure

HIV Negative groups:

  • Same criteria used for the HIV-negative groups as listed above.
  • No history of HIV infection.
  • Willing to undergo an HIV blood test, which must have a negative result.

Exclusion Criteria:

  • Women with positive urine pregnancy test within 7 days of study enrollment
  • Women who are within 6 months of being postpartum or who are currently breastfeeding
  • Subjects unable or unwilling to complete questionnaires and blood draw.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00859677


Locations
United States, California
Naval Medical Center San Diego
San Diego, California, United States, 92134
United States, Maryland
Walter Reed National Military Medical Center
Bethesda, Maryland, United States, 20889
Sponsors and Collaborators
Uniformed Services University of the Health Sciences
Infectious Diseases Clinical Research Program
National Institute of Allergy and Infectious Diseases (NIAID)
More Information

Publications:
Responsible Party: Brian Agan, Deputy Science Director, IDCRP, Uniformed Services University of the Health Sciences
ClinicalTrials.gov Identifier: NCT00859677     History of Changes
Other Study ID Numbers: IDCRP -023
First Posted: March 11, 2009    Key Record Dates
Last Update Posted: June 14, 2017
Last Verified: June 2017

Keywords provided by Brian Agan, Uniformed Services University of the Health Sciences:
HIV
Methicillin-resistant Staphylococcus aureus (MRSA)
HIV and Staphylococcus aureus infection

Additional relevant MeSH terms:
Infection
Communicable Diseases
HIV Infections
Staphylococcal Infections
Disease Susceptibility
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Gram-Positive Bacterial Infections
Bacterial Infections
Disease Attributes
Pathologic Processes
Methicillin
Anti-Bacterial Agents
Anti-Infective Agents